Drugs.com - Clinical Trials

BioArctic Receives Orphan Drug Designation for Exidavnemab the US

Stockholm, March 17, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple...

Mar 18, 2025 - 00:15
 0
BioArctic Receives Orphan Drug Designation for Exidavnemab the US
Stockholm, March 17, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple...
Read More

Tags:

Previous Article

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program...

Next Article

Risk of Developing Cancer Up for Children With Congenital Heart Disease

Related Posts

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR ...

Feb 9, 2025  0

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025  0

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Clinical Trial Initiation of Norovirus...

Mar 12, 2025  0